Cargando…

Drug resistance in targeted cancer therapies with RAF inhibitors

Hyperactive RAS/RAF/MEK/ERK signaling has a well-defined role in cancer biology. Targeting this pathway results in complete or partial regression of most cancers. In recent years, cancer genomic studies have revealed that genetic alterations that aberrantly activate the RAS/RAF/MEK/ERK signaling mai...

Descripción completa

Detalles Bibliográficos
Autores principales:	Degirmenci, Ufuk, Yap, Jiajun, Sim, Yuen Rong M., Qin, Shiru, Hu, Jiancheng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	OAE Publishing Inc. 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9094075/ https://www.ncbi.nlm.nih.gov/pubmed/35582307 http://dx.doi.org/10.20517/cdr.2021.36

Ejemplares similares

Targeting Aberrant RAS/RAF/MEK/ERK Signaling for Cancer Therapy
por: Degirmenci, Ufuk, et al.
Publicado: (2020)

The stability of R-spine defines RAF inhibitor resistance: A comprehensive analysis of oncogenic BRAF mutants with in-frame insertion of αC-β4 loop
por: Yap, Jiajun, et al.
Publicado: (2021)

The AMPK inhibitor overcomes the paradoxical effect of RAF inhibitors through blocking phospho–Ser-621 in the C terminus of CRAF
por: Yuan, Jimin, et al.
Publicado: (2018)

The MAPK and AMPK signalings: interplay and implication in targeted cancer therapy
por: Yuan, Jimin, et al.
Publicado: (2020)

Resistance to RAF inhibitors revisited
por: Hartsough, Edward, et al.
Publicado: (2013)

A Combination of Conformation-Specific RAF Inhibitors Overcome Drug Resistance Brought about by RAF Overexpression
por: Imoto, Hiroaki, et al.
Publicado: (2023)

Mechanisms of resistance to RAF inhibitors in melanoma
por: Aplin, Andrew E., et al.
Publicado: (2011)

Paradox-Breaking RAF Inhibitors that Also Target SRC Are Effective in Drug-Resistant BRAF Mutant Melanoma
por: Girotti, Maria Romina, et al.
Publicado: (2015)

Paradox-Breaking RAF Inhibitors that Also Target SRC Are Effective in Drug-Resistant BRAF Mutant Melanoma
por: Girotti, Maria Romina, et al.
Publicado: (2017)

Mixed lineage kinases activate MEK independently of RAF to mediate resistance to RAF inhibitors
por: Marusiak, Anna A., et al.
Publicado: (2014)

RAF inhibitors promote RAS-RAF interaction by allosterically disrupting RAF autoinhibition
por: Jin, Ting, et al.
Publicado: (2017)

The dimer-dependent catalytic activity of RAF family kinases is revealed through characterizing their oncogenic mutants
por: Yuan, Jimin, et al.
Publicado: (2018)

Targeting the Raf kinases in human cancer: the Raf dimer dilemma
por: Durrant, David E, et al.
Publicado: (2018)

Targeting B-Raf inhibitor resistant melanoma with novel cell penetrating peptide disrupters of PDE8A – C-Raf
por: Blair, Connor M., et al.
Publicado: (2019)

Perturbation biology nominates upstream–downstream drug combinations in RAF inhibitor resistant melanoma cells
por: Korkut, Anil, et al.
Publicado: (2015)

Tumor microenvironment induces innate RAF-inhibitor resistance through HGF secretion
por: Straussman, Ravid, et al.
Publicado: (2012)

Identification of PLX4032-resistance mechanisms and implications for novel RAF inhibitors
por: Choi, Jaehyuk, et al.
Publicado: (2014)

RAF inhibitors transactivate RAF dimers and ERK signaling in cells with wild-type BRAF
por: Poulikakos, Poulikos I., et al.
Publicado: (2010)

Exploiting metabolic vulnerabilities in breast cancers with NF1 loss
por: Yap, Yoon-Sim, et al.
Publicado: (2023)

Autophagy-Dependent Survival of Mutant B-Raf Melanoma Cells Selected for Resistance to Apoptosis Induced by Inhibitors against Oncogenic B-Raf
por: Ahn, Jun-Ho, et al.
Publicado: (2013)

Melanoma whole exome sequencing identifies (V600E)B-RAF amplification-mediated acquired B-RAF inhibitor resistance
por: Shi, Hubing, et al.
Publicado: (2012)

Structure and RAF family kinase isoform selectivity of type II RAF inhibitors tovorafenib and naporafenib
por: Tkacik, Emre, et al.
Publicado: (2023)

B-Raf and the inhibitors: from bench to bedside
por: Huang, Tiangui, et al.
Publicado: (2013)

RAF Kinase Inhibitor Protein in Myeloid Leukemogenesis
por: Zebisch, Armin, et al.
Publicado: (2019)

Neoadjuvant B-RAF and MEK Inhibitor Targeted Therapy for Adult Papillary Craniopharyngiomas: A New Treatment Paradigm
por: Calvanese, Francesco, et al.
Publicado: (2022)

Loss of USP28-mediated BRAF degradation drives resistance to RAF cancer therapies
por: Saei, Azad, et al.
Publicado: (2018)

Registered report: RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth
por: Bhargava, Ajay, et al.
Publicado: (2016)

Molecular Modeling Unveils the Effective Interaction of B-RAF Inhibitors with Rare B-RAF Insertion Variants
por: Scaini, Maria Chiara, et al.
Publicado: (2023)

The Raf‐like kinase Raf36 negatively regulates plant resistance against the oomycete pathogen Phytophthora parasitica by targeting MKK2
por: Li, Jinfang, et al.
Publicado: (2021)

RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)
por: Poulikakos, Poulikos I., et al.
Publicado: (2011)

Novel natural inhibitors targeting B-RAF(V600E) by computational study
por: Wu, Bo, et al.
Publicado: (2021)

PLX8394, a RAF inhibitor, inhibits enterovirus 71 replication by blocking RAF/MEK/ERK signaling
por: Wu, Chengyuan, et al.
Publicado: (2023)

PDCD6 cooperates with C-Raf to facilitate colorectal cancer progression via Raf/MEK/ERK activation
por: Wang, Xiaojuan, et al.
Publicado: (2020)

Arabidopsis Raf-Like Kinase Raf10 Is a Regulatory Component of Core ABA Signaling
por: Nguyen, Quy Thi Cam, et al.
Publicado: (2019)

Angiogenesis: A Pivotal Therapeutic Target in the Drug Development of Gynecologic Cancers
por: Kasherman, Lawrence, et al.
Publicado: (2022)

Effects of RAF inhibitors on PI3K/AKT signalling depend on mutational status of the RAS/RAF signalling axis
por: Fritsche-Guenther, Raphaela, et al.
Publicado: (2016)

Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma
por: Bollag, Gideon, et al.
Publicado: (2010)

Design and Synthesis of Hsp90 Inhibitors with B‐Raf and PDHK1 Multi‐Target Activity
por: Pinzi, Luca, et al.
Publicado: (2021)

Role of Raf-kinase inhibitor protein in colorectal cancer and its regulation by hydroxycamptothecine
por: Nie, Fang, et al.
Publicado: (2015)

Quantum chemical calculations, spectroscopic studies and molecular docking investigations of the anti-cancer drug quercitrin with B-RAF inhibitor
por: Govindammal, M., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_f2ovmaoea2rfdgivlhabsvlqlq